APA 6th Edition Reiner, Ž., Muačević-Katanec, D., Katanec, D. i Tedeschi-Reiner, E. (2012). JE LI HIPERTRIGLICERIDEMIJA ČIMBENIK RIZIKA OD KORONARNE BOLESTI SRCA?. Liječnički vjesnik, 134 (3-4), 0-0. Preuzeto s https://hrcak.srce.hr/172410
MLA 8th Edition Reiner, Željko, et al. "JE LI HIPERTRIGLICERIDEMIJA ČIMBENIK RIZIKA OD KORONARNE BOLESTI SRCA?." Liječnički vjesnik, vol. 134, br. 3-4, 2012, str. 0-0. https://hrcak.srce.hr/172410. Citirano 26.02.2020.
Chicago 17th Edition Reiner, Željko, Diana Muačević-Katanec, Davor Katanec i Eugenia Tedeschi-Reiner. "JE LI HIPERTRIGLICERIDEMIJA ČIMBENIK RIZIKA OD KORONARNE BOLESTI SRCA?." Liječnički vjesnik 134, br. 3-4 (2012): 0-0. https://hrcak.srce.hr/172410
Harvard Reiner, Ž., et al. (2012). 'JE LI HIPERTRIGLICERIDEMIJA ČIMBENIK RIZIKA OD KORONARNE BOLESTI SRCA?', Liječnički vjesnik, 134(3-4), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172410 (Datum pristupa: 26.02.2020.)
Vancouver Reiner Ž, Muačević-Katanec D, Katanec D, Tedeschi-Reiner E. JE LI HIPERTRIGLICERIDEMIJA ČIMBENIK RIZIKA OD KORONARNE BOLESTI SRCA?. Liječnički vjesnik [Internet]. 2012 [pristupljeno 26.02.2020.];134(3-4):0-0. Dostupno na: https://hrcak.srce.hr/172410
IEEE Ž. Reiner, D. Muačević-Katanec, D. Katanec i E. Tedeschi-Reiner, "JE LI HIPERTRIGLICERIDEMIJA ČIMBENIK RIZIKA OD KORONARNE BOLESTI SRCA?", Liječnički vjesnik, vol.134, br. 3-4, str. 0-0, 2012. [Online]. Dostupno na: https://hrcak.srce.hr/172410. [Citirano: 26.02.2020.]
Sažetak Although it is still not clear whether elevated serum triglycerides are directly atherogenic or not, the results of many studies indicate that they are undoubtedly an important risk factor /biomarker for coronary heart disease (CHD). Therefore, targeting hypertriglyceridaemia should be beneficial for subjects at high risk for CHD. Elevated triglycerides are often accompanied with low HDL cholesterol, particularly in high risk patients with diabetes type 2 and/or metabolic syndrome. Such a disturbance is called atherogenic dyslipidaemia and has an increasing prevalence. The treatment of hypertriglyceridaemia has to be focused primarily on intensive lifestyle changes (weight reduction in obesity, reduction of alcohol consumption as well as reduction of added sugars, fructose and trans-fatty acids, regular aerobic physical activity) by which reduction of up to 50% in triglycerides can be achieved. Subjects with high CHD risk who cannot lower hypertriglyceridaemia by lifestyle measures should be treated with pharmacological therapy. The available medications include fibrates, niacin and prescription omega-3 polyunsaturated fatty acids. If LDL cholesterol is elevated too, combination therapy is needed. Based upon recent studies in such patients a combination of a statin with fenofibrate and/or omega-3 fatty acids can be recommended.